Coherus BioSciences, Inc. (CHRS) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Coherus BioSciences is a commercial-stage biopharmaceutical company focused on immunotherapies. The company's commercial portfolio currently consists of UDENYCA (a biosimilar to Neulasta) and LOQTORZI (a PD-1 inhibitor for nasopharyngeal carcinoma). During the period, the company divested its YUSIMRY (immunology) and CIMERLI (ophthalmology) franchises. The company is currently facing a temporary supply interruption for UDENYCA due to capacity constraints at a third-party contract manufacturing organization (CMO).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Net Revenue | $70.8 million | $74.6 million | $212.8 million | $165.7 million |
| Net Income (Loss) | $(10.8) million | $(39.6) million | $79.2 million | $(158.2) million |
| Gross Margin | 71% | 56% | 61% | 55% |
| Operating Loss | $(6.4) million | $(32.0) million | $(69.4) million | $(134.3) million |
| Cash and Equivalents | $97.7 million | $102.9 million (Dec 2023) | N/A | |
| Total Debt (Carrying Value) | $264.5 million | $473.4 million (Dec 2023) | N/A |
Note: YTD 2024 Net Income includes a $176.6 million gain from asset sales (CIMERLI and YUSIMRY).
Material Changes vs. Prior Period
- Revenue Composition: Q3 2024 revenue decreased 5% year-over-year primarily due to the divestiture of YUSIMRY and CIMERLI, which contributed $41.4 million in Q3 2023. This was partially offset by a 100% increase in UDENYCA revenue ($33.1 million increase) and $5.8 million in LOQTORZI sales.
- Asset Sales: The company recognized a net gain of $176.6 million on the sale of the CIMERLI franchise (to Sandoz) and YUSIMRY franchise (to HKF) during the first nine months of 2024.
- Debt Restructuring: The company fully repaid its $250 million 2027 Term Loans in May 2024, incurring a $12.6 million loss on debt extinguishment. Concurrently, it entered a new $38.7 million 2029 Term Loan and a Revenue Purchase and Sale Agreement for $37.5 million.
- Cost Reductions: Selling, General, and Administrative (SG&A) expenses decreased by $13.5 million in Q3 2024 compared to Q3 2023, driven by lower headcount and professional service fees.
Guidance, Outlook, and Risks
- Supply Chain Disruption: A critical risk is the temporary supply interruption of UDENYCA, which accounted for 93.4% of Q3 revenue. Production is expected to resume in early November 2024, with a new CMO expected to begin commercial supply in Q1 2025. Management expects Q4 2024 revenue to be significantly lower than Q3 2024 due to depleted channel inventory.
- Liquidity: As of September 30, 2024, the company held $97.7 million in cash and cash equivalents. Management believes this, combined with product sales and ATM offering proceeds, is sufficient to fund operations for at least the next 12 months.
- Outlook: The company expects R&D expenses to be lower in 2024 than 2023 due to cost containment and the termination of the TIGIT program, partially offset by pipeline development costs. SG&A is also expected to be lower due to divestitures and reduced headcount.
- Legal Proceedings: The company has an accrual of $6.4 million related to a demand letter from Zinc Health Services regarding UDENYCA sales from 2020-2021.
Investor Verification Checklist
- UDENYCA Supply Timeline: Verify the actual resumption of shipments from the primary CMO in November 2024 and the FDA authorization timeline for the secondary CMO.
- Q4 Revenue Impact: Assess the severity of the revenue decline in Q4 2024 resulting from the supply interruption and channel depletion.
- Debt Covenants: Monitor compliance with the financial covenants of the new 2029 Term Loan, specifically the requirement to maintain certain levels of cash and cash equivalents.
- LOQTORZI Growth: Track the commercial uptake of LOQTORZI as the company transitions away from reliance on the divested franchises.
- Legal Accruals: Monitor the status of the Zinc Health Services claim and any potential changes to the $6.4 million accrual.